[{"id":"ed7a2006-5e7e-462b-a374-549a902e3ba9","acronym":"STX-478-101","url":"https://clinicaltrials.gov/study/NCT05768139","created_at":"2024-01-30T16:19:49.137Z","updated_at":"2025-02-25T13:41:27.084Z","phase":"Phase 1/2","brief_title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05768139 - STX-478-101","lead_sponsor":"Scorpion Therapeutics, Inc.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • tersolisib (LY4064809)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2025-02-21"}]